T1	PHYS 7 18	interaction
#1	AnnotatorNotes T1	C0687133
T2	CHEM 29 45	intégrine α 4β 1
#2	AnnotatorNotes T2	C0209606
T3	DISO 97 109	inflammation
#3	AnnotatorNotes T3	C0021368
T4	ANAT 123 132	cérébrale
#4	AnnotatorNotes T4	C0006104
T5	PHYS 174 186	interactions
#5	AnnotatorNotes T5	C0687133
T6	DISO 215 254	inflammation du système nerveux central
#6	AnnotatorNotes T6	C0178264
T7	ANAT 231 254	système nerveux central
#7	AnnotatorNotes T7	C0927232
T8	ANAT 257 260	SNC
#8	AnnotatorNotes T8	C0927232
T9	DISO 277 280	SEP
#9	AnnotatorNotes T9	C0026769
T10	PHYS 295 306	interaction
#10	AnnotatorNotes T10	C0687133
T11	CHEM 314 330	intégrine α 4β 1
#11	AnnotatorNotes T11	C0209606
T12	CHEM 340 348	VCAM - 1
#12	AnnotatorNotes T12	C0078056
T13	CHEM 351 357	CS - 1
#13	AnnotatorNotes T13	C0172284
T14	CHEM 361 373	ostéopontine
#14	AnnotatorNotes T14	C0069676
T15	ANAT 442 452	leucocytes
#15	AnnotatorNotes T15	C0023516
T16	ANAT 534 539	tissu
#16	AnnotatorNotes T16	C0040300
T17	ANAT 543 546	SNC
#17	AnnotatorNotes T17	C0927232
T18	CHEM 551 558	TYSABRI
#18	AnnotatorNotes T18	C1529600
T19	PROC 593 603	traitement
#19	AnnotatorNotes T19	C0087111
T20	DISO 618 637	sclérose en plaques
#20	AnnotatorNotes T20	C0026769
T21	DISO 720 728	handicap
#21	AnnotatorNotes T21	C0231172
T22	PROC 809 819	traitement
#22	AnnotatorNotes T22	C0087111
T23	LIVB 835 842	groupes
#23	AnnotatorNotes T23	C1257890
T24	LIVB 846 854	patients
#24	AnnotatorNotes T24	C0030705
T25	LIVB 870 878	Patients
#25	AnnotatorNotes T25	C0030705
T26	PROC 906 916	traitement
#26	AnnotatorNotes T26	C0087111
T27	CHEM 945 960	interféron bêta
#27	AnnotatorNotes T27	C0015980
T28	LIVB 969 977	patients
#28	AnnotatorNotes T28	C0030705
T29	PROC 1081 1091	traitement
#29	AnnotatorNotes T29	C0087111
T30	DISO 1124 1131	lésions
#30	AnnotatorNotes T30	C0175677
T31	PROC 1158 1161	IRM
#31	AnnotatorNotes T31	C0024485
T32	ANAT 1162 1171	cérébrale
#32	AnnotatorNotes T32	C0006104
T33	DISO 1186 1192	lésion
#33	AnnotatorNotes T33	C0221198
T34	PROC 1209 1218	injection
#34	AnnotatorNotes T34	C0021485
T35	CHEM 1222 1232	Gadolinium
#35	AnnotatorNotes T35	C0016911
T36	LIVB 1239 1247	Patients
#36	AnnotatorNotes T36	C0030705
T37	DISO 1263 1282	sclérose en plaques
#37	AnnotatorNotes T37	C0026769
T38	DISO 1432 1442	lésion ( s
#38	AnnotatorNotes T38	C0221198
T39	PROC 1467 1476	injection
#39	AnnotatorNotes T39	C0021485
T40	CHEM 1480 1490	Gadolinium
#40	AnnotatorNotes T40	C0016911
T41	PROC 1499 1502	IRM
#41	AnnotatorNotes T41	C0024485
T42	ANAT 1503 1512	cérébrale
#42	AnnotatorNotes T42	C0006104
T43	PROC 1596 1599	IRM
#43	AnnotatorNotes T43	C0024485
T44	PROC 1685 1690	étude
#44	AnnotatorNotes T44	C2603343
T45	PROC 1702 1707	étude
#45	AnnotatorNotes T45	C2603343
T46	CHEM 1764 1771	placebo
#46	AnnotatorNotes T46	C1696465
T47	LIVB 1792 1800	patients
#47	AnnotatorNotes T47	C0030705
T48	DISO 1813 1816	SEP
#48	AnnotatorNotes T48	C0026769
T49	PROC 1937 1942	étude
#49	AnnotatorNotes T49	C2603343
T50	DISO 2038 2046	handicap
#50	AnnotatorNotes T50	C0231172
T51	DISO 2137 2144	maladie
#51	AnnotatorNotes T51	C0012634
T52	PROC 2162 2183	examens neurologiques
#52	AnnotatorNotes T52	C0027853
T53	DISO 2295 2302	lésions
#53	AnnotatorNotes T53	C0221198
T54	CHEM 2318 2328	gadolinium
#54	AnnotatorNotes T54	C0303704
T55	DISO 2368 2375	lésions
#55	AnnotatorNotes T55	C0221198
T56	PROC 2478 2483	étude
#56	AnnotatorNotes T56	C2603343
T57	DISO 2530 2536	SEP RR
#57	AnnotatorNotes T57	C0751967
T58	DISO 2575 2583	Handicap
#58	AnnotatorNotes T58	C0231172
T59	DISO 2662 2669	lésions
#59	AnnotatorNotes T59	C0221198
T60	LIVB 2861 2869	patients
#60	AnnotatorNotes T60	C0030705
T61	PROC 2879 2884	étude
#61	AnnotatorNotes T61	C2603343
T62	CHEM 2958 2969	natalizumab
#62	AnnotatorNotes T62	C1172734
T63	LIVB 2979 2987	patients
#63	AnnotatorNotes T63	C0030705
T64	DISO 2988 2997	souffrant
#64	AnnotatorNotes T64	C0857256
T65	DISO 3001 3004	SEP
#65	AnnotatorNotes T65	C0026769
T66	ANAT 3026 3034	sériques
#66	AnnotatorNotes T66	C0005767
T67	PROC 3167 3177	traitement
#67	AnnotatorNotes T67	C0087111
T68	LIVB 3382 3389	groupes
#68	AnnotatorNotes T68	C1257890
T69	LIVB 3407 3415	patients
#69	AnnotatorNotes T69	C0030705
T70	DISO 3429 3432	SEP
#70	AnnotatorNotes T70	C0026769
T71	CHEM 3486 3497	natalizumab
#71	AnnotatorNotes T71	C1172734
T72	LIVB 3512 3520	patients
#72	AnnotatorNotes T72	C0030705
T73	PHYS 3583 3592	clairance
#73	AnnotatorNotes T73	C0025515
T74	PHYS 3833 3836	âge
#74	AnnotatorNotes T74	C0001779
T75	PHYS 3852 3870	fonction hépatique
#75	AnnotatorNotes T75	C0232741
T76	ANAT 3861 3870	hépatique
#76	AnnotatorNotes T76	C1012978
T77	ANAT 3874 3880	rénale
#77	AnnotatorNotes T77	C0022646
T78	CHEM 3907 3916	anticorps
#78	AnnotatorNotes T78	C0003241
T79	CHEM 3924 3935	natalizumab
#79	AnnotatorNotes T79	C1172734
T80	CHEM 3974 3983	anticorps
#80	AnnotatorNotes T80	C0003241
T81	CHEM 3991 4002	natalizumab
#81	AnnotatorNotes T81	C1172734
T82	CHEM 4034 4045	natalizumab
#82	AnnotatorNotes T82	C1172734
T83	PHYS 4063 4068	poids
#83	AnnotatorNotes T83	C0005910
T84	PHYS 4197 4206	clairance
#84	AnnotatorNotes T84	C0025515
T85	PHYS 4236 4245	clairance
#85	AnnotatorNotes T85	C0025515
T86	CHEM 4307 4316	anticorps
#86	AnnotatorNotes T86	C0003241
T87	CHEM 4324 4335	natalizumab
#87	AnnotatorNotes T87	C1172734
T88	PHYS 4378 4387	clairance
#88	AnnotatorNotes T88	C0025515
T89	CHEM 4391 4402	natalizumab
#89	AnnotatorNotes T89	C1172734
T90	ANAT 4463 4471	sériques
#90	AnnotatorNotes T90	C0005767
T91	CHEM 4475 4486	natalizumab
#91	AnnotatorNotes T91	C1172734
T92	LIVB 4505 4513	patients
#92	AnnotatorNotes T92	C0030705
T93	CHEM 4538 4547	anticorps
#93	AnnotatorNotes T93	C0003241
T94	CHEM 4612 4623	natalizumab
#94	AnnotatorNotes T94	C1172734
T95	LIVB 4657 4663	enfant
#95	AnnotatorNotes T95	C0008059
T96	ANAT 4688 4693	rénal
#96	AnnotatorNotes T96	C0022646
T97	ANAT 4697 4706	hépatique
#97	AnnotatorNotes T97	C1012978
T98	PROC 4725 4746	échanges plasmatiques
#98	AnnotatorNotes T98	C0032113
T99	ANAT 4734 4746	plasmatiques
#99	AnnotatorNotes T99	C0032105
T100	PHYS 4754 4763	clairance
#100	AnnotatorNotes T100	C0025515
T101	CHEM 4804 4815	natalizumab
#101	AnnotatorNotes T101	C1172734
T102	PROC 4842 4847	étude
#102	AnnotatorNotes T102	C2603343
T103	LIVB 4856 4864	patients
#103	AnnotatorNotes T103	C0030705
T104	DISO 4877 4880	SEP
#104	AnnotatorNotes T104	C0026769
T105	CHEM 4904 4914	médicament
#105	AnnotatorNotes T105	C0013227
T106	PROC 4923 4944	échanges plasmatiques
#106	AnnotatorNotes T106	C0032113
T107	ANAT 4932 4944	plasmatiques
#107	AnnotatorNotes T107	C0032105
T108	PROC 5076 5082	études
#108	AnnotatorNotes T108	C2603343
T109	DISO 5151 5170	arrêt du traitement
#109	AnnotatorNotes T109	C1699848
T110	PROC 5160 5170	traitement
#110	AnnotatorNotes T110	C0087111
T111	DISO 5193 5204	observation
#111	AnnotatorNotes T111	C0941132
T112	PROC 5234 5255	échanges plasmatiques
#112	AnnotatorNotes T112	C0032113
T113	ANAT 5243 5255	plasmatiques
#113	AnnotatorNotes T113	C0032105
T114	PHYS 5277 5300	migration lymphocytaire
#114	AnnotatorNotes T114	C0302123
T115	ANAT 5287 5300	lymphocytaire
#115	AnnotatorNotes T115	C0024264
T116	CHEM 5407 5418	natalizumab
#116	AnnotatorNotes T116	C1172734
T117	ANAT 5460 5471	lymphocytes
#117	AnnotatorNotes T117	C0024264
T118	ANAT 5495 5510	globules blancs
#118	AnnotatorNotes T118	C0023516
T119	DISO 5526 5538	hypersplénie
#119	AnnotatorNotes T119	C0020532
T120	CHEM 5677 5685	toxiques
#120	AnnotatorNotes T120	C0032346
T121	PROC 5702 5708	études
#121	AnnotatorNotes T121	C2603343
T122	LIVB 5727 5733	souris
#122	AnnotatorNotes T122	C0025929
T123	CHEM 5758 5769	natalizumab
#123	AnnotatorNotes T123	C1172734
T124	PHYS 5792 5802	croissance
#124	AnnotatorNotes T124	C0018270
T125	DISO 5824 5834	métastases
#125	AnnotatorNotes T125	C0027627
T126	DISO 5838 5845	tumeurs
#126	AnnotatorNotes T126	C0027651
T127	DISO 5854 5862	mélanome
#127	AnnotatorNotes T127	C0025202
T128	DISO 5866 5890	leucémie lymphoblastique
#128	AnnotatorNotes T128	C0023448
T129	CHEM 5898 5909	natalizumab
#129	AnnotatorNotes T129	C1172734
T130	CHEM 5935 5945	clastogène
#130	AnnotatorNotes T130	C0008904
T131	CHEM 5949 5957	mutagène
#131	AnnotatorNotes T131	C0026879
T132	PROC 5967 5981	tests d ’ Ames
#132	AnnotatorNotes T132	C0598910
T133	DISO 6004 6030	aberrations chromosomiques
#133	AnnotatorNotes T133	C0008626
T134	ANAT 6034 6051	cellules humaines
#134	AnnotatorNotes T134	C0007634
T135	LIVB 6043 6051	humaines
#135	AnnotatorNotes T135	C0086418
T136	DISO 6131 6144	prolifération
#136	AnnotatorNotes T136	C0334094
T137	ANAT 6148 6165	lignées tumorales
#137	AnnotatorNotes T137	C0085983
T138	DISO 6156 6165	tumorales
#138	AnnotatorNotes T138	C0027651
T139	CHEM 6166 6179	intégrine α 4
#139	AnnotatorNotes T139	C1531499
T140	DISO 6202 6214	cytotoxicité
#140	AnnotatorNotes T140	C0596402
T141	PROC 6248 6259	avortements
#141	AnnotatorNotes T141	C0392535
T142	PROC 6296 6301	étude
#142	AnnotatorNotes T142	C2603343
T143	PROC 6310 6315	étude
#143	AnnotatorNotes T143	C2603343
T144	LIVB 6332 6337	singe
#144	AnnotatorNotes T144	C0026447
T145	DISO 6349 6356	gravide
#145	AnnotatorNotes T145	C0549206
T146	CHEM 6415 6426	natalizumab
#146	AnnotatorNotes T146	C1172734
T147	DISO 6450 6456	anémie
#147	AnnotatorNotes T147	C0002871
T148	DISO 6463 6488	diminution des plaquettes
#148	AnnotatorNotes T148	C2751262
T149	ANAT 6478 6488	plaquettes
#149	AnnotatorNotes T149	C0005821
T150	ANAT 6523 6527	rate
#150	AnnotatorNotes T150	C0037993
T151	ANAT 6566 6570	foie
#151	AnnotatorNotes T151	C0023884
T152	ANAT 6577 6583	thymus
#152	AnnotatorNotes T152	C0040113
T153	PHYS 6650 6678	hématopoïèse extramédullaire
#153	AnnotatorNotes T153	C0018952
T154	ANAT 6679 6688	splénique
#154	AnnotatorNotes T154	C0037993
T155	DISO 6708 6726	atrophie du thymus
#155	AnnotatorNotes T155	C0272419
T156	ANAT 6720 6726	thymus
#156	AnnotatorNotes T156	C0040113
T157	PHYS 6754 6766	hématopoïèse
#157	AnnotatorNotes T157	C0018951
T158	ANAT 6793 6803	plaquettes
#158	AnnotatorNotes T158	C0005821
T159	LIVB 6965 6976	nouveau-nés
#159	AnnotatorNotes T159	C0003065
T160	PROC 6858 6866	traitées
#160	AnnotatorNotes T160	C0087111
T161	CHEM 6874 6885	natalizumab
#161	AnnotatorNotes T161	C1172734
T162	PHYS 6899 6907	mise-bas
#162	AnnotatorNotes T162	C0005615
T163	DISO 6949 6955	anémie
#163	AnnotatorNotes T163	C0002871
T164	LIVB 7068 7073	homme
#164	AnnotatorNotes T164	C0086418
T165	CHEM 7107 7118	natalizumab
#165	AnnotatorNotes T165	C1172734
T166	CHEM 7123 7142	Phosphate de sodium
#166	AnnotatorNotes T166	C0074757
T167	CHEM 7171 7190	Phosphate de sodium
#167	AnnotatorNotes T167	C0074757
T168	CHEM 7218 7236	Chlorure de sodium
#168	AnnotatorNotes T168	C0037494
T169	CHEM 7237 7251	Polysorbate 80
#169	AnnotatorNotes T169	C0032601
T170	CHEM 7261 7264	Eau
#170	AnnotatorNotes T170	C0043047
T171	CHEM 7270 7292	préparation injectable
#171	AnnotatorNotes T171	C0086466
T172	PROC 7282 7292	injectable
#172	AnnotatorNotes T172	C0021485
T173	CHEM 7297 7304	TYSABRI
#173	AnnotatorNotes T173	C1529600
T174	CHEM 7346 7357	médicaments
#174	AnnotatorNotes T174	C0013227
T175	ANAT 1149 1151	T2
#175	AnnotatorNotes T175	C0459936
T176	ANAT 1575 1577	T2
#176	AnnotatorNotes T176	C0459936
T177	DISO 97 132	inflammation pathologique cérébrale
#177	AnnotatorNotes T177	C0014038
T178	PROC 1158 1171	IRM cérébrale
#178	AnnotatorNotes T178	C0412675
T179	PROC 1499 1512	IRM cérébrale
#179	AnnotatorNotes T179	C0412675
T180	PROC 2276 2279	IRM
#180	AnnotatorNotes T180	C0024485
T181	ANAT 2393 2395	T2
#181	AnnotatorNotes T181	C0459936
T182	CHEM 7254 7258	E433
#182	AnnotatorNotes T182	C0032601
T183	LIVB 6837 6848	nouveau-nés
#183	AnnotatorNotes T183	C0003065
T184	PROC 5577 5591	études in vivo
#184	AnnotatorNotes T184	C0681829
T185	PROC 6112 6127	essais in vitro
#185	AnnotatorNotes T185	C0681828
T186	ANAT 6332 6348	singe cynomolgus
#186	AnnotatorNotes T186	C0024399	
T187	LIVB 6324 6331	femelle
#187	AnnotatorNotes T187	C0015780
T188	ANAT 2349 2351	T1
#188	AnnotatorNotes T188	C0459933
T189	DISO 1553 1571	charge lésionnelle
#189	AnnotatorNotes T189	C0175677
T190	ANAT 461 471	parenchyme
#190	AnnotatorNotes T190	C0933845
T191	ANAT 472 480	cérébral
#191	AnnotatorNotes T191	C0006104
T192	PROC 1685 1690;1717 1727;1747 1756	étude randomisée contrôlée
#192	AnnotatorNotes T192	C0206035
